Biocartis

Genomic Health will gain exclusive worldwide rights to develop and sell an IVD version of its Oncotype DX breast cancer test on Biocartis' Idylla platform.

The company is working to secure US pharmaceutical partners for its Idylla system and expects its US activities to begin driving growth by the end of 2017

The firm reported an 88 percent increase in product sales, but this was offset by a 79 percent drop in collaboration revenues.

The panel, developed by collaborator Janssen, is expected to improve detection of influenza and respiratory syncytial virus.

The first assay to be developed under the new five-year strategic partnership is a solid biopsy breast cancer assay designed to guide drug selection.

The lung cancer test, which can detect 51 EGFR mutations, is the fifth assay for cancer that the Belgian molecular diagnostics firm has CE marked.

Biocartis and MRCT are planning to develop a range of molecular diagnostic assays for Biocartis' fully automated Idylla platform.

The subsidiary is being formed in support of Biocartis' recent US distribution deal with Thermo Fisher Scientific.

The firm said that the test may be validated as a prognostic test for colorectal cancer and a predictive test for cancer immunotherapies. 

A decline in collaboration revenues more than offset revenue gains for the company's Idylla platform and test cartridges.

Pages

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.